{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:28:22Z","timestamp":1777552102343,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T00:00:00Z","timestamp":1454544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s12072-016-9704-y","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T15:22:17Z","timestamp":1454599337000},"page":"799-806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment"],"prefix":"10.1007","volume":"10","author":[{"given":"Yuko","family":"Takami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Mikagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Saitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,4]]},"reference":[{"key":"9704_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. J Clin 2005;55:74\u2013108","journal-title":"J Clin"},{"key":"9704_CR2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000343866","volume":"3","author":"N Akamatsu","year":"2014","unstructured":"Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer 2014;3:108\u2013118","journal-title":"Liver Cancer"},{"key":"9704_CR3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.sla.0000171307.37401.db","volume":"242","author":"K Hasegawa","year":"2005","unstructured":"Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005;242:252\u2013259","journal-title":"Ann Surg"},{"key":"9704_CR4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00534-012-0527-5","volume":"20","author":"Y Takami","year":"2013","unstructured":"Takami Y, Ryu T, Wada Y, Saitsu H. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci 2013;20:332\u2013341","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"9704_CR5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ajg.2011.425","volume":"107","author":"S Shiina","year":"2012","unstructured":"Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569\u2013577","journal-title":"Am J Gastroenterol"},{"key":"9704_CR6","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.3748\/wjg.v20.i37.13453","volume":"20","author":"S Murata","year":"2014","unstructured":"Murata S, Mine T, Sugihara F, Yasui D, Yamaguchi H, Ueda T, et al. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 2014;20:13453\u201313465","journal-title":"World J Gastroenterol"},{"issue":"359","key":"9704_CR7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"24","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;24(359):378\u2013390","journal-title":"N Engl J Med"},{"key":"9704_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/jhep.2000.9409","volume":"32","author":"K Ikeda","year":"2000","unstructured":"Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228\u2013232","journal-title":"Hepatology"},{"key":"9704_CR9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/j.1572-0241.2006.00647.x","volume":"101","author":"G Chen","year":"2006","unstructured":"Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797\u20131803","journal-title":"Am J Gastroenterol"},{"key":"9704_CR10","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199606133342402","volume":"334","author":"Y Muto","year":"1996","unstructured":"Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561\u20131567","journal-title":"N Engl J Med"},{"key":"9704_CR11","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1940-6207.CAPR-11-0340","volume":"4","author":"S Ninomiya","year":"2011","unstructured":"Ninomiya S, Shimizu M, Imai K, Takai K, Shiraki M, Hara T, et al. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Cancer Prev Res (Phila) 2011;4:2092\u20132100","journal-title":"Cancer Prev Res (Phila)"},{"key":"9704_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000071373","volume":"37","author":"S Gately","year":"2003","unstructured":"Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179\u2013192","journal-title":"Prog Exp Tumor Res"},{"key":"9704_CR13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1026575610124","volume":"19","author":"S Gately","year":"2000","unstructured":"Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19\u201327","journal-title":"Cancer Metastasis Rev"},{"key":"9704_CR14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10585-011-9404-x","volume":"28","author":"OO Ogunwobi","year":"2011","unstructured":"Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and Cox-2 pathways. Clin Exp Metastasis 2011;28:721\u2013731","journal-title":"Clin Exp Metastasis"},{"key":"9704_CR15","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2174\/138161206777698972","volume":"12","author":"M Mutoh","year":"2006","unstructured":"Mutoh M, Takahashi M, Wakabayashi K. Roles of prostanoids in colon carcinogenesis and their potential targeting for cancer chemoprevention. Curr Pharm Des 2006;12:2375\u20132382","journal-title":"Curr Pharm Des"},{"key":"9704_CR16","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.2174\/138161207782360627","volume":"13","author":"M Breinig","year":"2007","unstructured":"Breinig M, Schirmacher P, Kern MA. Cyclooxygenase-2 (Cox-2)\u2013a therapeutic target in liver cancer. Curr Pharm Des 2007;13:3305\u20133315","journal-title":"Curr Pharm Des"},{"key":"9704_CR17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2957\/kanzo.53.781","volume":"53","author":"T Ryu","year":"2012","unstructured":"Ryu T, Takami Y, Tateishi M, Wada Y, Saitsu H. Efficacy of Cox-2 inhibitor, Meloxicam, for recurrent hepatocellular carcinoma after curative treatment. Kanzo 2012;53:781\u2013783","journal-title":"Kanzo"},{"key":"9704_CR18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3892\/or.2013.2497","volume":"30","author":"H Yoshiji","year":"2013","unstructured":"Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, et al. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Oncol Rep 2013;30:545\u2013552","journal-title":"Oncol Rep"},{"key":"9704_CR19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jhep.2004.12.025","volume":"42","author":"H Yoshiji","year":"2005","unstructured":"Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 2005;42:687\u2013693","journal-title":"J Hepatol"},{"key":"9704_CR20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/omi.2010.0095","volume":"15","author":"A Giacalone","year":"2011","unstructured":"Giacalone A, Montalto G, Giannitrapani L, Balasus D, Terranova A, Cervello M, et al. Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-\u03b1, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. OMICS 2011;15:193\u2013196","journal-title":"OMICS"},{"key":"9704_CR21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11010-010-0629-9","volume":"347","author":"H Akk\u0131z","year":"2011","unstructured":"Akk\u0131z H, Bayram S, Bekar A, Akg\u00f6ll\u00fc E, \u00dclger Y. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem 2011;347:201\u2013208","journal-title":"Mol Cell Biochem"},{"key":"9704_CR22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10620-006-9184-3","volume":"52","author":"S Pazirandeh","year":"2007","unstructured":"Pazirandeh S, Khettry U, Gordon FD, Resnick RH, Murray JE, Sheth SG. Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States. Dig Dis Sci 2007;52:220\u2013227","journal-title":"Dig Dis Sci"},{"key":"9704_CR23","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.3748\/wjg.v12.i32.5113","volume":"12","author":"M Cervello","year":"2006","unstructured":"Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006;12:5113\u20135121","journal-title":"World J Gastroenterol"},{"key":"9704_CR24","first-page":"4005","volume":"5","author":"M Kondo","year":"1999","unstructured":"Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, et al. Increased expression of Cox-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5:4005\u20134012","journal-title":"Clin Cancer Res"},{"key":"9704_CR25","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/hep.510290355","volume":"29","author":"H Koga","year":"1999","unstructured":"Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688\u2013696","journal-title":"Hepatology"},{"key":"9704_CR26","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1440-1746.2006.04367.x","volume":"22","author":"S Morinaga","year":"2007","unstructured":"Morinaga S, Tarao K, Yamamoto Y, Nakamura Y, Rino Y, Miyakawa K, et al. Overexpressed cyclo-oxygenase-2 in the background liver is associated with the clinical course of hepatitis C virus-related cirrhosis patients after curative surgery for hepatocellular carcinoma. J Gastroenterol Hepatol 2007;22:1249\u20131255","journal-title":"J Gastroenterol Hepatol"},{"key":"9704_CR27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1155\/2010\/872570","volume":"24","author":"YF He","year":"2010","unstructured":"He YF, Jin J, Wei W, Chang Y, Hu B, Ji CS, et al. Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis. Can J Gastroenterol 2010;24:435\u2013440","journal-title":"Can J Gastroenterol"},{"key":"9704_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204078","author":"B M\u00f6ller","year":"2013","unstructured":"M\u00f6ller B, Pruijm M, Adler S, Scherer A, Villiger PM, Finckh A. Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study. Ann Rheum Dis 2013. doi: 10.1136\/annrheumdis-2013-204078","journal-title":"Ann Rheum Dis"},{"key":"9704_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.11.007","author":"A Lanas","year":"2014","unstructured":"Lanas A, Carrera P, Arguedas Y, Garcia S, Bujanda L, Calvet X, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 2014. doi: 10.1016\/j.cgh.2014.11.007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9704_CR30","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11938-014-0029-4","volume":"12","author":"CJ Gargallo","year":"2014","unstructured":"Gargallo CJ, Sostres C, Lanas A. Prevention and treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol 2014;12:398\u2013413","journal-title":"Curr Treat Options Gastroenterol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-016-9704-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-016-9704-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T08:13:39Z","timestamp":1567584819000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-016-9704-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,4]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["9704"],"URL":"https:\/\/doi.org\/10.1007\/s12072-016-9704-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,4]]}}}